Lv31
210 积分 2023-05-29 加入
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial
14天前
已完结
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
14天前
已完结
A Preclinical Immunogenicity Study of the Recombinant Human Papillomavirus Nine-Valent Virus-like Particle Vaccine
1个月前
已完结
Safety, reactogenicity, and immunogenicity of ZR-202-CoV and ZR-202a-CoV recombinant vaccines compared with Comirnaty®: a randomized, observer-blind, controlled, phase 1 study
7个月前
已完结
Next-generation sequencing sheds light on the interaction between virus and cell during foot-and-mouth disease virus persistent infection
8个月前
已完结
Exopolysaccharide from Cryptococcus heimaeyensis S20 induces autophagic cell death in non‐small cell lung cancer cells via ROS/p38 and ROS/ERK signalling
8个月前
已完结
Single-Cell Sequencing Yields Insights in the Evolution of Foot-and-Mouth Disease Virus Persistent Infection
9个月前
已完结
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial
10个月前
已完结
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial
1年前
已完结
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial
1年前
已完结
皖公网安备34019202002308
